Pfizer / BioNTech’s anti-Covid vaccine had a 90.7% efficacy rate in preventing symptomatic infection among children aged 5 to 11, according to data from a clinical study that the American Pfizer presented at the ‘Fda drug agency whose response is awaited. The news bounces on the US media.
Children under 12 involved in the trial received a dose of 10 micrograms, one third lower than that given to older populations (30 micrograms). According to the results submitted by the manufacturers to the FDA, the dosage was shown to be safe and the reported side effects were mild. Of the 2,268 children recruited, double the proportion of the placebo group received the vaccine. In the control group, 16 children contracted Covid, while among the vaccinated, 3 became ill: an efficacy of over 90%.
Pfizer has submitted the first data ahead of a meeting scheduled for next week, in which the advisory committee of the FDA will decide whether to recommend the agency to grant authorization to Comirnaty * in the under 12 bracket. If the FDA says yes, the The ball will be passed on to the Centers for Disease Control and Prevention (Cdc) which next month will provide the operational indications for the campaign in children.
#Vaccine #years #Pfizer #effective #Fda #response